Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(50%)

Results Posted

100%(1 trials)

Phase Distribution

Phase 3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 3Large-scale testing

2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Detailed Status

Active, not recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

active_not_recruiting150%

completed150%

Recent Activity

1 active trials

Showing 2 of 2

active_not_recruitingphase_3

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

NCT03992755

completedphase_3

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604

Clinical Trials (2)

Showing 2 of 2 trials

NCT03992755Phase 3

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Active Not Recruiting

NCT03399604Phase 3

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Completed

All 2 trials loaded

Drug Details

Intervention Type: Drug
Total Trials: 2